Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy.

In this trial ( Table 1 ), ARNI administration did not result in a significantly lower rate of total hospitalizations for heart failure and was not connected with significantly lower cardiovascular mortality (a trend towards benefit in reduction of primary events was observed, but the differences did not reach statistical significance: 894 primary events in the ARNI group versus 1009 primary events in the valsartan group; HR 0.87; 95% CI: 0.75-1.01; p = 0.06).

also in 111,027 other papers